knowledge

As one of the largest and oldest medical device companies in the world, Medtronic has a foot in almost every clinical area.

The device maker with a market valuation of nearly $100 billion sells pacemakers, spinal cord stimulators, stents, monitors. Name a device, and they probably make it. The behemoth is ubiquitous in health care, but its size can make innovation sluggish. Medtronic has tried to become more streamlined in recent years — the company announced plans last year to spin off its patient monitoring and respiratory businesses, which Reuters recently reported, citing unnamed sources, may go to the Carlyle Group, a private equity firm.

advertisement

Still, the device giant is immersed in many different specialties, including diabetes and high blood pressure, where the company has experienced some setbacks. Medtronic has sold old-school insulin pumps since the 1980s and therefore developed robust dosing algorithms, but has never successfully built a tubeless pump. The company plans to buy Korean patch pump maker EOFlow, but EOFlow is enmeshed in a patent battle with Insulet. A federal judge blocked EOFlow from selling its wearable patch pumps earlier this month.

Get unlimited access to award-winning journalism and exclusive events.